Real-Time Stock News, Analysis & Price Movements

Gilead Sciences News - May 25, 2026

Gilead Shares Climb 3% Following Landmark FDA Hepatitis Drug Approval
GILD

Gilead Shares Climb 3% Following Landmark FDA Hepatitis Drug Approval

The FDA granted accelerated approval to Gilead Sciences’ Hepcludex (bulevirtide-gmod). Hepcludex is the first and only U.S.-approved therapy for adults with...
Gilead secures Hepcludex approval, first US hepatitis delta treatment
GILD

Gilead secures Hepcludex approval, first US hepatitis delta treatment

Gilead Sciences received accelerated FDA approval for Hepcludex on May 24, 2026. Hepcludex is the first and only treatment for chronic hepatitis delta virus in...